Chardan Capital Has Negative Outlook of COYA FY2025 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Investment analysts at Chardan Capital lowered their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a note issued to investors on Wednesday, May 14th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.57) per share for the year, down from their previous estimate of ($1.03). Chardan Capital has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $257.88 million for the quarter, compared to the consensus estimate of $2.63 million.

Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday, April 22nd.

Coya Therapeutics Stock Up 1.0%

Shares of NASDAQ:COYA opened at $5.93 on Monday. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The stock has a market capitalization of $99.18 million, a PE ratio of -9.12 and a beta of 0.49. The firm’s 50 day moving average price is $6.05 and its 200-day moving average price is $6.17.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently bought and sold shares of COYA. Tower Research Capital LLC TRC increased its position in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after acquiring an additional 4,777 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in Coya Therapeutics during the 1st quarter valued at about $65,000. XTX Topco Ltd bought a new position in Coya Therapeutics during the 4th quarter valued at about $59,000. Jane Street Group LLC purchased a new stake in Coya Therapeutics in the 4th quarter worth about $74,000. Finally, Northern Trust Corp lifted its stake in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.